BiotechTube
DS Biopharma

DS Biopharma

Dublin, Ireland· Est.
dsbiopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DS Biopharma is a private, clinical-stage biotech company headquartered in Dublin, Ireland, built on a deep foundation in lipid science. The company is advancing a pipeline of small molecule therapeutics, with its lead programs targeting inflammatory skin diseases such as atopic dermatitis. While pre-revenue, it has established strategic partnerships and continues to progress its candidates through clinical development to address significant unmet medical needs.

DermatologyInflammatory Diseases

Technology Platform

Proprietary lipid science platform focused on modulating fatty acid pathways (e.g., DGLA metabolism) to treat inflammatory and metabolic diseases.

Opportunities

The large and growing atopic dermatitis market presents a significant opportunity for a safe, topical, steroid-sparing therapy like DS107.
Success in dermatology could validate the lipid platform for expansion into other inflammatory and metabolic diseases with high unmet need.

Risk Factors

Key risks include clinical trial failure of lead assets, intense competition in dermatology from large pharma and novel biologics, and reliance on external funding and partnerships for survival and commercialization due to its pre-revenue status.

Competitive Landscape

DS Biopharma competes in the crowded inflammatory skin disease space against major players with biologics (Dupixent, Adbry) and JAK inhibitors (Opzelura, Cibinqo). Its differentiation lies in a novel lipid-based mechanism, but it must prove superior safety/efficacy to gain market share.

More companies in Small Molecule Drugs →More companies in Ireland →